teladoc health inc. - TDOC
TDOC
Close Chg Chg %
5.42 0.15 2.77%
Closed Market
5.57
+0.15 (2.77%)
Volume: 4.42M
Last Updated:
Mar 25, 2026, 3:59 PM EDT
Company Overview: teladoc health inc. - TDOC
TDOC Key Data
| Open $5.56 | Day Range 5.39 - 5.61 |
| 52 Week Range 4.40 - 9.77 | Market Cap $966.91M |
| Shares Outstanding 178.40M | Public Float 174.48M |
| Beta 2.13 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.14 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 6.40M |
TDOC Performance
| 1 Week | 4.11% | ||
| 1 Month | 5.89% | ||
| 3 Months | -21.77% | ||
| 1 Year | -31.15% | ||
| 5 Years | -96.85% |
TDOC Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
27
Full Ratings ➔
About teladoc health inc. - TDOC
Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.
TDOC At a Glance
Teladoc Health, Inc.
155 East 44th Street
New York, New York 10017
| Phone | 1-203-635-2002 | Revenue | 2.53B | |
| Industry | Medical/Nursing Services | Net Income | -200,322,000.00 | |
| Sector | Health Services | Employees | 5,600 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
TDOC Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.488 |
| Price to Book Ratio | 0.901 |
| Price to Cash Flow Ratio | 4.25 |
| Enterprise Value to EBITDA | 7.006 |
| Enterprise Value to Sales | 0.59 |
| Total Debt to Enterprise Value | 0.697 |
TDOC Efficiency
| Revenue/Employee | 451,781.607 |
| Income Per Employee | -35,771.786 |
| Receivables Turnover | 12.546 |
| Total Asset Turnover | 0.737 |
TDOC Liquidity
| Current Ratio | 2.686 |
| Quick Ratio | 2.592 |
| Cash Ratio | 1.93 |
TDOC Profitability
| Gross Margin | 55.111 |
| Operating Margin | -6.458 |
| Pretax Margin | -9.31 |
| Net Margin | -7.918 |
| Return on Assets | -5.837 |
| Return on Equity | -13.927 |
| Return on Total Capital | -8.258 |
| Return on Invested Capital | -8.128 |
TDOC Capital Structure
| Total Debt to Total Equity | 75.064 |
| Total Debt to Total Capital | 42.878 |
| Total Debt to Total Assets | 33.545 |
| Long-Term Debt to Equity | 74.267 |
| Long-Term Debt to Total Capital | 42.423 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Teladoc Health Inc. - TDOC
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 2.41B | 2.60B | 2.57B | 2.53B | |
Sales Growth
| +18.41% | +8.13% | -1.26% | -1.54% | |
Cost of Goods Sold (COGS) incl D&A
| 1.00B | 1.10B | 1.12B | 1.14B | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 270.64M | 351.32M | 382.84M | 376.43M | |
Depreciation
| 26.04M | 25.39M | 19.48M | 25.67M | |
Amortization of Intangibles
| 244.60M | 325.93M | 363.37M | 350.76M | |
COGS Growth
| +17.03% | +9.71% | +2.53% | +0.96% | |
Gross Income
| 1.41B | 1.51B | 1.44B | 1.39B | |
Gross Income Growth
| +19.40% | +7.00% | -4.02% | -3.49% | |
Gross Profit Margin
| +58.45% | +57.84% | +56.23% | +55.11% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 1.63B | 1.72B | 1.65B | 1.56B | |
Research & Development
| 333.63M | 348.52M | 307.27M | 277.92M | |
Other SG&A
| 1.30B | 1.37B | 1.35B | 1.28B | |
SGA Growth
| +15.31% | +4.99% | -3.63% | -5.80% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| 13.43B | 38.05M | 812.10M | 99.56M | |
EBIT after Unusual Expense
| (13.65B) | (248.55M) | (1.02B) | (262.95M) | |
Non Operating Income/Expense
| (859.00K) | 51.23M | 51.04M | 47.14M | |
Non-Operating Interest Income
| - | 46.78M | 57.07M | 36.77M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 9.27M | 22.28M | 23.80M | 19.71M | |
Interest Expense Growth
| -88.47% | +140.37% | +6.83% | -17.18% | |
Gross Interest Expense
| 9.27M | 22.28M | 23.80M | 19.71M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (13.66B) | (219.61M) | (993.65M) | (235.53M) | |
Pretax Income Growth
| -3,452.09% | +98.39% | -352.47% | +76.30% | |
Pretax Margin
| -567.69% | -8.44% | -38.67% | -9.31% | |
Income Tax
| (3.81M) | 760.00K | 7.59M | (35.21M) | |
Income Tax - Current - Domestic
| 3.01M | 1.44M | 5.24M | (328.00K) | |
Income Tax - Current - Foreign
| 1.02M | 1.23M | 3.50M | 6.53M | |
Income Tax - Deferred - Domestic
| (4.87M) | 1.44M | (574.00K) | (38.93M) | |
Income Tax - Deferred - Foreign
| (2.97M) | (3.35M) | (571.00K) | (2.48M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (13.66B) | (220.37M) | (1.00B) | (200.32M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (13.66B) | (220.37M) | (1.00B) | (200.32M) | |
Net Income Growth
| -3,085.58% | +98.39% | -354.35% | +79.99% | |
Net Margin Growth
| -567.53% | -8.47% | -38.97% | -7.92% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (13.66B) | (220.37M) | (1.00B) | (200.32M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (13.66B) | (220.37M) | (1.00B) | (200.32M) | |
EPS (Basic)
| -84.6016 | -1.339 | -5.8702 | -1.1368 | |
EPS (Basic) Growth
| -2,996.46% | +98.42% | -338.40% | +80.63% | |
Basic Shares Outstanding
| 161.46M | 164.58M | 170.56M | 176.22M | |
EPS (Diluted)
| -84.6016 | -1.339 | -5.8702 | -1.1368 | |
EPS (Diluted) Growth
| -2,996.46% | +98.42% | -338.40% | +80.63% | |
Diluted Shares Outstanding
| 161.46M | 164.58M | 170.56M | 176.22M | |
EBITDA
| 43.28M | 140.82M | 174.06M | 213.04M | |
EBITDA Growth
| +323.46% | +225.40% | +23.60% | +22.40% | |
EBITDA Margin
| +1.80% | +5.41% | +6.77% | +8.42% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 6.95 | |
| Number of Ratings | 27 | Current Quarters Estimate | -0.341 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -0.896 | |
| Last Quarter’s Earnings | -0.14 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.14 | Next Fiscal Year Estimate | -0.736 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 19 | 19 | 20 | 18 |
| Mean Estimate | -0.34 | -0.23 | -0.90 | -0.74 |
| High Estimates | -0.24 | -0.18 | -0.71 | -0.41 |
| Low Estimate | -0.40 | -0.26 | -1.08 | -1.21 |
| Coefficient of Variance | -15.23 | -9.72 | -8.84 | -23.30 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 7 | 6 | 5 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 20 | 20 | 22 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Hold | Hold |
SEC Filings for Teladoc Health Inc. - TDOC
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Teladoc Health Inc. - TDOC
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 13, 2026 | Charles Divita CHIEF EXECUTIVE OFFICER; Director | 367,022 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 13, 2026 | Charles Divita CHIEF EXECUTIVE OFFICER; Director | 392,515 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 13, 2026 | Charles Divita CHIEF EXECUTIVE OFFICER; Director | 364,784 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.49 per share | 2,002,664.16 |
| Mar 13, 2026 | Charles Divita CHIEF EXECUTIVE OFFICER; Director | 195,803 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 13, 2026 | Charles Divita CHIEF EXECUTIVE OFFICER; Director | 43,703 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 13, 2026 | Charles Divita CHIEF EXECUTIVE OFFICER; Director | 18,210 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 13, 2026 | Kelly M. Bliss President, U.S. Group Health | 15,596 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 13, 2026 | Kelly M. Bliss President, U.S. Group Health | 10,398 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | 106,196 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | 181,661 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | 22,260 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | 27,458 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | 73,222 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | 19,435 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | 84,747 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $5.12 per share | 433,904.64 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | 111,394 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Mar 4, 2026 | Kelly M. Bliss President, U.S. Group Health | 105,010 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Feb 20, 2026 | Michael Scott Smith Director | 53,648 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |